Invention Grant
- Patent Title: Quinoxaline compounds as type III receptor tyrosine kinase inhibitors
-
Application No.: US16340685Application Date: 2017-10-09
-
Publication No.: US10689362B2Publication Date: 2020-06-23
- Inventor: Shao-Zheng Peng , Chu-Bin Liao , Hung-Kai Chen , Chen-Hsuan Ho , Hung-Jyun Huang , Shian-Yi Chiou
- Applicant: Development Center for Biotechnology
- Applicant Address: TW Taipei
- Assignee: Development Center for Biotechnology
- Current Assignee: Development Center for Biotechnology
- Current Assignee Address: TW Taipei
- Agency: Liang Legal Group, PLLC
- International Application: PCT/US2017/055809 WO 20171009
- International Announcement: WO2018/071348 WO 20180419
- Main IPC: A61K31/44
- IPC: A61K31/44 ; A61K31/498 ; A61P35/00 ; C07D241/40 ; C07D241/44 ; C07D401/06 ; C07D401/12 ; C07D241/52 ; C07D401/14 ; C07D413/04 ; C07D413/14 ; C07D401/04 ; C07D413/12 ; C07D403/04 ; C07D405/12 ; C07D409/12 ; C07D403/12 ; C07D403/14
Abstract:
A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.
Public/Granted literature
- US20190308949A1 QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS Public/Granted day:2019-10-10
Information query
